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Abstract
Background: The mass colorectal cancer screening program was implemented in 2008 in France, targeting 16
million French people aged between 50 and 74. The current adhesion is insufficient and the participation rate is
even lower among the underserved population, increasing health inequalities within our health care system. Patient
Navigation programs have proved their efficiency to promote the access to cancer screening and diagnosis.
Methods/Design: The purpose of the study is to assess the implementation of a patient navigation intervention
that has been described in another cultural environment and another health care system. The main objective of
the program is to increase the colorectal cancer screening participation rate among the deprived population
through the intervention of a navigator to promote the Fecal Occult Blood Test (FOBT) and complementary exams.
We performed a multisite cluster randomized controlled trial, with three groups (one experimental group and two
control groups) for 18 months.
Discussion: The study attempts to give a better understanding of the adhesion barriers to colorectal cancer
screening among underserved populations. If this project is cost-effective, it could create a dynamic based on peer
approaches that could be developed for other cancer screening programs and other chronic diseases.
Trial registration: NCT02369757
Keywords: Colorectal cancer screening, Patient navigation, Realistic evaluation, Implementation research, Health
inequalities, Randomized control study
Background
Colorectal cancer (CRC) is the third most common can-
cer diagnosed and the second leading cause of cancer
death in both men and women in France, according to
the GLOBOCAN estimates [1]. Approximately, 42 000
new cases were diagnosed in 2012, predominantly men
and 17 500 deaths were attributed to CRC [1].
Since 2008, CRC mass screening has been imple-
mented in France. This population-based program tar-
gets men and women aged from 50 to 74 who receive a
standardized invitation letter, every 2 years, to encourage
them to consult their general practitioner (GP). The GP
delivers a screening test. People who don’t send their
test to the screening center receive a reminder letter.
They then receive the test at home within 6 months
following the date of the first invitation. The test used is
the FOBT, followed by a colonoscopy in case of a posi-
tive test result.
Several studies have universally shown that FOBT,
followed by colonoscopy in case of a positive test result
can reduce CRC mortality [2–6]. But to be efficient, a
high participation of the target population is required
for these screening programs, at least 50 % [7].
In France, for the period 2009–2010, 17 million
French people were invited to participate in the CRC
screening program. The national participation rate was
only 33.8 % (5.14 million) whereas the national objective
was to reach a participation rate of 60 % in 2013.
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Significant disparities were recorded. The women partic-
ipated more than the men (36.5 % vs. 31.4 %). Among
men, older people (over 70) participated more than the
younger ones. Women between 60 and 64 years old, par-
ticipated more. Moreover, participation rates varied
widely according to the regions.
The factors affecting FOBT screening program partici-
pation have been analyzed. Gender, age, marital status,
educational status, social status and economical status
can influence participation [8]. In France, the correlation
between socioeconomic status and participation rate has
been observed [9].
It is interesting to note that France is one of the
Western European countries where socioeconomic
gradient – measured by the educational status – has the
highest impact on mortality [10]. Moreover, social in-
equalities impact cancer rates, including colorectal cancer
[11]. As a matter of fact, France is one of the European
countries where educational status, among all risk factors
considered, has the highest impact on cancer mortality.
Patient Navigation (PN) is a patient-centered health-
care service delivery model that centers on reducing
barriers to cancer care [12–15]. The first “Patient Navi-
gation” program was established in New York in the
early 1990s, by Freeman, a surgical oncologist at Harlem
Hospital [15]. The development of the PN concept was
related to the findings of the American Cancer Society
National Hearings on Cancer in the Poor (Program No
Need to Die). Based on these hearings, the first PN
program was built. It focused on the critical window of
opportunity to save lives from cancer by eliminating bar-
riers to timely diagnosis and treatment for low-income
populations [16]. The program was composed of naviga-
tors who were from the community or culturally similar
to the population served. The patient navigator was de-
fined as an individual who could educate and empower
patients, serving as their advocate in navigating the
health care system. This intervention succeeded in im-
proving access to breast and colorectal cancer screening
for the deprived population. It helped improve survival
rates by 5 years [17, 18]. Moreover, this approach is con-
sidered as an effective means to reduce inequalities in
the USA [19]. These interventions have been increas-
ingly adopted throughout the Unites States, Canada [20]
and China [21, 22].
We hypothesize that inequalities generated by general
prevention measures can be offset with specific mea-
sures, thanks to peer education which targets population
from underserved areas.
The primary objective of this study is to determine
effectiveness of a PN Program on CRC screening
participation among the underserved population.
The secondary aims are: 1) to perform a realistic
evaluation of an innovating intervention, of which the
effectiveness has been demonstrated by several random-
ized studies in another health care system 2) to assess
the implementation into a specific context 3) to identify
factors favoring or hindering the effectiveness of the
intervention.




COLONAV is a population-based cluster randomized
control study. It assesses the effectiveness of an inter-
vention previously described and evaluated in another
cultural environment and in another health care system,
as regards CRC screening attendance.
Three parallel groups will be compared:
– one experimental group with intervention
– two control groups without intervention
Selection of study sites and participants
The study will include men and women aged from 50
to 74 years old, invited to screening and living in
underserved areas. The research will be conducted in
the following five districts because of their different
socioeconomic characteristics:
– A rural district (L’Ardèche, 313 578 inhabitants)
– A district with an industrial economy and low
development (La Loire, 746 115 inhabitants)
– A district with a tertiary economy and high
development (Le Rhône, 1 708 671 inhabitants)
– A district where CRC screening has been
implemented for a long time (La Côte d’Or,
524 144 inhabitants)
– One of the suburban districts of the capital
(Le Val-de-Marne, 1 318 537 inhabitants)
In each district, the geographical areas to be studied
will be determined by matching the criteria in terms of
the socioeconomic indicators and the low participation
rate for CRC screening. In France, each district is di-
vided into IRIS zones, ie aggregated units for statistical
information used as a system for dividing the country
into units of equal size (2000 residents per basic unit).
We will use the French European Deprivation Index
(EDI) [23] to determine the most deprived IRIS zones
(quintiles 4 and 5 of the Index corresponding to the
most disadvantaged areas) and the participation rates of
each zone to select the lowest ones.
Sample size
We estimated that the intervention would be relevant if
it provided an 8 % absolute increase in the colorectal
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cancer screening participation rate (22 % in the control
group and 30 % in the intervention group). With a two-
sided α risk of 0.05 and a β risk of 0.1, and assuming an
intraclass correlation coefficient for clusters of 0.004 and
a mean of 500 patients per cluster (assuming an average
of 2000 people per IRIS zone and percentage of people
between 50 and 75 years equal to 25 % of the total popu-
lation), we needed 4 clusters per group (2000 people per
group). Taking into account the three groups (one inter-
vention group and two control groups) and stratified by
department gives a total number included about 30 000
individuals.
We establish that the number of IRIS zones needed to
meet the objectives of the study is 20 intervention IRIS
zones and 40 control IRIS zones [24].
So, for each district, we will randomly select:
– four contiguous intervention IRIS zones
– eight control IRIS zones divided into two groups




The conceptual model of PN intervention was developed
by Fiscella [25] to articulate the relations between pro-
gram inputs, navigation activities, and specific outcomes.
In this model, the author distinguished two domains of
navigator’s services: instrumental/logistical, reflecting
technical competence, and interpersonal/educational,
reflecting the relational alliance [26] (Fig. 1).
The main role of the navigators is to promote CRC
screening among the target population to increase
participation rates in these areas. The missions of the
navigators are to contact individuals living in the inter-
vention area and invited by the screening structure and
to guide them to the realization of the screening test.
Navigators’ activities will be: 1) to establish partner-
ships with local associations, religious places, health cen-
ters, health fairs, GPs… in order to participate in local
events and to meet the target population 2) to find a
committee room to meet people who are in need 3) to
communicate by phone or face-to-face with the target
population 4) to provide personalized assistance to each
person in order to help them to overcome obstacles in
the realization of the screening test (psychological, finan-
cial or logistical barriers) 5) to collect patient socio-
demographic information.
Control group
Men and women in the control group will receive the
invitation and the usual standard information document.
The invitation is an administrative letter sent by all the
screening management structures when men and
women are scheduled to be invited to participate in the




We will diagnose local needs in the five selected districts
before the intervention. A research team conducted
semi-structured interviews with relevant stakeholders
(individuals representing the target population, GPs,
local actors of associations) in order to accurately assess
the needs of the target population. The goal of this
Fig. 1 Conceptual model of patient navigation (Fiscella 2011)
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diagnosis was to have a better understanding of barriers
and obstacles of the target population but also of the dif-
ferent stakeholders about the screening.
Recruitment and training of navigators
The strategy is to recruit and train one navigator per dis-
trict. Candidates’ recruitment will be done by means of
job description that will be widely diffused. The profile
desired is a peer, i.e. a person corresponding to the tar-
get population of the study, living in the intervention
zones. The district committees of “La Ligue contre le
Cancer” (a French non-governmental organization which
promotes cancer screening, gives support to patients
and funds research, will be in charge of recruiting each
navigator). Navigators will receive formal training for
one week on all issues related to the following: the navi-
gation process, cancer generalities, CRC screening,
counseling and support to patients as needed.
Patient navigation intervention
Navigators will be hosted by the district committees of
“La Ligue contre le Cancer” during the intervention
(18 months). In each of these structures, a supervisor
will be assigned to each navigator. The intervention will
mainly consist of: outreaching the target population and
accompanying the target population to be screened.
In order to gather information about the navigators
‘experiences (their good practice and challenges they are
facing) meetings will be organized with the researchers
of the study. Navigators will regularly update a field
journal and a database. They will participate in the
practice exchange days and develop quarterly progress
reports.
Realistic evaluation
In this study we will use a realist evaluation approach,
based on Pawson and Tilley’s work [27]. This theory-
driven approach focuses evaluation on the study of what
works, for whom and in what circumstances. These
relationships are constructed as Context-Mechanism-
Outcome configurations [28]. Considering the evaluation
design, multidisciplinary teams will be associated (public
health teams, human and social sciences teams and
economic research teams.).
Both quantitative and qualitative data will be collected
to perform the realist evaluation.
Outcomes assessments
Primary outcome
To assess the effectiveness of the intervention, the
primary outcome will be measured by the difference
between before/after participation rates in the inter-
vention zones and in the control zones. Other criteria
will be used according to the recommendations made
by the National Patient Navigation Leadership Sum-
mit (NPNLS) and published in Cancer in 2011 [29]:
time to participate, participation in the whole proced-
ure, time to complete the colonoscopy after a positive
FOBT test result.
Eighteen months after the beginning of the interven-
tion, each screening management structure, in charge of
sending the invitation to individuals included in the
mass screening program, will collect the participation
status of the men and women included in the study.
Each district structure has a database with the contact
details of all individuals, eligible to receive an invitation
to the national screening program. After the beginning
of the intervention, the 18 month-participation rates will
be measured, in selected areas. The following items will
be measured: program coverage rate (percentage of
people guided by navigators), screening participation
rate, percentage of patients who get screened after the
navigator intervention, colonoscopy completion rate.
Secondary outcome
The secondary outcomes for this study include 1) context
of patient-related evaluation, as recommended by the
Patient-Reported Outcomes Working Group (PROWG) of
the Navigation program [30] 2) evaluation of evidence-
informed practice 3) ethical evaluation 4) cost-effectiveness
5) organizational analysis.
A patient-related context evaluation will use measures
reported by the target population in contact with naviga-
tors according to the PROWG [25]. The following fields
will be explored: habits and fears regarding cancer and
screening, cultural aspects, satisfaction about the inter-
vention. An approach with questionnaires will be used,
completed by semi-structured interviews. Given the lack
of validated questionnaires in French, we will use a non-
validated questionnaire.
In view of a future implementation of the program
after its evaluation and to identify variances with the ini-
tial program, a researcher will perform an ethnographic
evaluation. In total, 10 days of tracking will be done in
order to know the detailed practice of the navigators, in-
cluding the way they behave in order to adapt to local
context for two reasons: (a) to take into consideration
the potential future implementation of the program after
its evaluation; b) to identify the potential variances with
the initial program.
An ethical evaluation will include focus group and in-
terviews with navigators lead by a team specializing in
ethics of public health. Indeed, a project to correct social
inequalities in health, through the intervention of peers,
raises at least two ethical issues: 1) justice-related chal-
lenges: if justice is the guiding value of the intervention
that aims to tackle health disparities, it can also trigger
potentially unfair identity assignment and stigmatization.
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2) Such a community-based intervention also raises
challenges regarding the trust-building process.
An economic assessment of the intervention will in-
vestigate the cost-effectiveness of this program.
An organizational analysis will take the recommenda-
tions of the US program of navigation into account, to
ensure comparability with other interventions [31]. The
objective is to determine the conditions of implementa-
tion, sustainability and reproducibility of the program.
The method of investigation is a qualitative method.
Observational data will be collected at different mo-
ments: preparation of the intervention, recruitment of
the navigators, during and after the intervention.
Statistical analysis
Quantitative analysis
All collected individual variables will be described by fre-
quency (%) for categorical variables, and mean (SD) and
median (Q1 -Q3) for quantitative variables. The data will
be summarized separately in two tables: one for the
period before intervention, and another for the period
after intervention. The effectiveness of the intervention
will be measured comparing the delta of before-after
participation rate in intervention area and control areas.
Completion time of the exams (screening test and colon-
oscopy) between intervention areas and control areas
before and after the intervention will also be compared.
The difference in participation will be analyzed by logis-
tic regression analysis methods taking into account the
interactions between the period and area. The influence
of other collected variables will be tested using univari-
ate tests (Chi2 or Fisher test for categorical variables and
Student or Wilcoxon test for quantitative variables). A
multivariate model will be implemented in order to take
possible confounding factors into account. Analysis of
participation time will be done in two ways: firstly by
taking the censored data with a Cox model into account
and secondly with a ANOVA model (on the subgroup of
patients who participate). The level of statistical signifi-
cance will be of 5 %.
Qualitative analysis
First, recorded interviews will be transcribed in verba-
tim. Transcripts will be read holistically, and then line-
by-line to extract significant statements from the
interviews, following established guidelines for a the-
matic analysis. These statements will be used to generate
specific codes, and each transcript will then be coded
using this thematic coding scheme. The themes emer-
ging from the first interviews will help to refine the
interview guide used for the next set of interviews. The
latter will in turn be used to inform the next set and so
on. Data analysis will be performed simultaneously and
continually with the data collection, in order to identify
the arising of data saturation. The gathered information
will then be categorized into five main themes, based on
the objectives of the study.
Cost effectiveness analysis
In order to estimate the cost-effectiveness of the imple-
mentation of such a program, marginal costs, with
encryption on the actual cost, observed during the in-
stallation, as well as a projection on a routine cost will
be taken into account.
Organizational analysis
The content of the interviews with navigators and insti-
tutional partners will be subject for a qualitative analysis
by the IRaMuTeQ software. A statistical analysis of dif-
ferent texts will be performed in order to generally
describe the corpus (number of texts, occurrences, of
forms …). This will determine the navigators’profiles, as
well as a hierarchical organizational structure. It will also
create a theoretical model for action.
Discussion
This study aims: 1) to implement a PN intervention for
which the efficacy has been demonstrated in a different
context 2) to assess the effectiveness of the intervention
in this context 3) to identify the context characteristics
that may interact with the effect of the intervention (fac-
tors favoring or hindering). The ColoNav project should
make it possible to determine if the patient navigation
program is suitable and if it works in the context of the
French healthcare system. It should allow us to identify
the effects of the context and to give details concerning
the specific favoring and hindering factors. Finally,
ColoNav will allow the creation of a new enhanced pro-
gram. If this intervention is estimated as being cost effect-
ive, it could create new dynamics for peer approaches.
The latter could be developed for the screening program
of other cancers or other chronic diseases.
Abbreviations
CRC, colorectal cancer; EDI, European Deprivation Index; FOBT, fecal occult
blood test; GP, general practitioner; INCA, Institut National du Cancer; NPNLS,
National Patient Navigation Leadership Summit; PN, patient navigation;
PROWG, Patient-Reported Outcomes Working Group
Funding
The French National Cancer Institute (INCA) and the French National
Association against Cancer (Ligue National contre Le Cancer) supported
this study.
Availability of data and materials
All external and internal authors had full access to all of the data (including
statistical reports and tables) in the study and can take responsibility for the
integrity of the data and the accuracy of the data analysis.
Authors’ contributions
FC, AB and SR conceived the project. FC and AB coordinated the study. SR
and CA managed the research teams. MP conducted the local diagnosis. VB,
Allary et al. BMC Cancer  (2016) 16:416 Page 5 of 6
JK, VD, NL, MP, YB participated to design and conduct the realistic
evaluation. MO and FT performed the statistical analysis. CA and AB were the
major contributors in writing the manuscript. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethical approval and consent to participate
The Ethical Committee of Saint Etienne University Hospital (IORG0007394)
approved this study on January 10th 2013, which waived the need for signed
informed consent according to French law, since the study involved healthy
men and women and proposed no treatment.
Author details
1Hygée Centre, Lucien Neuwirth Cancer Institut- ICLN, CIC 1408 INSERM,
108bis avenue A. Raimond, 42270 Saint-Priest-en-Jarez, France. 2Gustave
Roussy Institut, 114 rue Edouard Vaillant, 94800 Villejuif, France. 3COACTIS,
Lumière University Lyon 2, 16 avenue Berthelot, 69007 Lyon, France. 4EA
4148 - S2HEP, University Lyon 1/Ecole Normale Supérieure de Lyon, 43,
Boulevard du 11 novembre 1918, 69622 Villeurbanne cedex, France.
Received: 6 January 2016 Accepted: 29 June 2016
References
1. Ferlay, J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo
M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer
Incidence and Mortality Worldwide: IARC CancerBase No. 11 [online].
International Agency for Research on Cancer, Lyon (France) 2013.
Available from www.http://globocan.iarc.fr.
2. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal
cancer by screening for fecal occult blood. Minnesota Colon Cancer Control
Study. N Engl J Med. 1993;328(19):1365–71.
3. Kronborg O, Jorgensen OD, Fenger C, Rasmussen M. Randomized study of
biennial screening with a faecal occult blood test: results after nine
screening rounds. Scand J Gastroenterol. 2004;39(9):846–51.
4. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled
trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;
348(9040):1472–7.
5. Faivre J, Dancourt V, Lejeune C, et al. Reduction in colorectal cancer
mortality by fecal occult blood screening in a French controlled study.
Gastroenterology. 2004;126(7):1674–80.
6. Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of
colorectal cancer screening using the fecal occult blood test (hemoccult):
an update. Am J Gastroenterol. 2008;103(6):1541–9.
7. Faivre J, Lepage C, Dancourt V. Le dépistage organisé du cancer colorectal
en France et en Europe : historique et état des lieux. Numéro thématique –
Dépistage organisé du cancer colorectal en France. Bull Epidemiol Hebdo.
2009;13:02–3.
8. Von Euler-Chelpin M, Brasso K, Lynge E. Determinants of participation in
colorectal cancer screening with faecal occult blood testing. J Public Health
(Oxf). 2010;32:395–405.
9. Pornet C, Dejardin O, Morlais F, Bouvier V, Launoy G. Socioeconomic
determinants for compliance to colorectal cancer screening. A multilevel
analysis. J Epidemiol Community Health. 2010;64:318–24.
10. Mackenbach JP, Stirbu I, Roskam AJ, Schaap MM, Menvielle G, Leinsalu M,
Kunst AE. European Union Working Group on Socioeconomic Inequalities in
Health. Socioeconomic inequalities in health in 22 European countries. N
Engl J Med. 2008;358(23):2468–81.
11. Menvielle G, Kunst AE, Stirbu I, Strand BH, Borrell C, Regidor E, Leclerc A,
Esnaola S, Bopp M, Lundberg O, Artnik B, Costa G, Deboosere P, Martikainen
P, Mackenbach JP. Educational differences in cancer mortality among
women and men: a gender pattern that differs across Europe. Br J Cancer.
2008;98(5):1012–9.
12. Dohan D, Schrag D. Using navigators to improve care of underserved
patients : current practices and approaches. Cancer. 2005;104(4):848–55.
13. Wells KJ, Battaglia TA, Dudley DJ, Garcia R, Greene A, Calhoun E,
Mandelblatt JS, Paskett ED, Raich PC. Raich PC; Patient Navigation Research
Program. Patient navigation: state of the art or is it science? Cancer. 2008;
113(8):1999–2010.
14. Paskett ED, Harrop JP, Wells KJ. Patient navigation: an update on the state
of the science. CA Cancer J Clin. 2011;61(4):237–49.
15. Freeman HP, Muth BJ, Kerner JF. Expanding access to cancer screening and
clinical follow-up among the medically underserved. Cancer Pract. 1995;3:19–30.
16. Freeman HP, Rodriguez RL. History and principles of patient navigation.
Cancer. 2011;117(15 Suppl):3539–42.
17. Nash D, Azeez S, Vlahov D, Schori M. Evaluation of an Intervention to
Increase Screening Colonoscopy in an Urban Public Hospital Setting. J
Urban Health. 2006;83(2):231–43.
18. Jandorf L, Gutierrez Y, Lopez J, Christie J, Itzkowitz SH. Use of a Patient
Navigator to Increase Colorectal Cancer Screening in an Urban
Neighborhood Health Clinic. J Urban Health. 2005;82(2):216–24.
19. Natale-Pereira A, Enard KR, Nevarez L, Jones LA. The role of patient navigators
in eliminating health disparities. Cancer. 2011;117(15 Suppl):3543–52.
20. Lorhan S, Cleghom L, Fitch M, Pang K, McAndrew A, Applin-Poole J, Ledwell
E, Mitchell R, Wright M. Moving the agenda forward for cancer patient
navigation: understanding volunteer and peer navigation approaches. J
Cancer Educ. 2013;28(1):84–91.
21. Fang CY, Ma GX, Tan Y, Chi N. A multifaceted intervention to increase
cervical cancer screening among Korean women. Cancer Epidemiol
Biomarkers Prev. 2007;16(6):1298–302.
22. Ma GX, Yin L, Gao W, Tan Y, Liu R, Fang C, Ma XS. Workplace-based breast
cancer screening intervention in China. Cancer Epidemiol Biomarkers Prev.
2012;21(2):358–67.
23. Pornet C, Delapierre C, Dejardin O, Grosclaude P, Launay L, Guittet L, Lang
T, Launoy G. Construction of an adaptable European transnational ecological
deprivation index : The French version. J Epidemiol Community Health. 2012;
66(11):982–9.
24. Hayes RJ, Bennett S. Simple sample size calculation for cluster-randomized
trials. Int J Epidemiol. 1999;28(2):319–26.
25. Jean-Pierre P, Hendren S, Fiscella K, Loader S, Rousseau S, Schwartzbauer B,
et al. Understanding the processes of patient navigation to reduce
disparities in cancer care: perspectives of trained navigators from the field. J
Cancer Educ. 2011;26(1):111–20.
26. Pawson R, Tilley N. Realistic Evaluation, Sage, 1997.
27. Connelly JB. Evaluating complex public health interventions: theory,
methods and scope of realist enquiry. J Eval Clin Pract. 2007;13(6):935–41.
28. Battaglia TA, Burhansstipanov L, Murrell SS, Dwyer AJ. Caron SE. Prevention
and Early Detection Workgroup, National Patient Navigation Leadership
Summit. Assessing the impact of patient navigation: prevention and early
detection metrics. Cancer. 2011;117(15 Suppl):3553–64.
29. Fiscella K, Ransom S, Jean-Pierre P, Cella D, Stein K, Bauer JE, et al. Patient-
reported outcome measures suitable to assessment of patient navigation.
Cancer. 2011;117(15):3603–17.
30. Whitley E, Valverde P, Wells K, Williams L, Teschner T, Shih YC. Establishing
common cost measures to evaluate the economic value of patient
navigation programs. Cancer. 2011;117(15 Suppl):3618–25.
31. Creswell JW, Hanson WE, Clark Plano VL, Morales A. Qualitative Research
Designs Selection and Implementation. Couns Psychol. 2007;35:236–64.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Allary et al. BMC Cancer  (2016) 16:416 Page 6 of 6
